FdaApplication
BLA 125118
Identifiers
- fda_app_no: BLA125118
Properties
| Property | Value |
|---|---|
| applicant_name | Bristol-Myers Squibb Company |
| application_type | BLA |
| approval_date | 2005-12-23 |
Revenue by product
ORENCIA
| Period | Revenue |
|---|---|
| Q2 2026 | $1.0B |
| Q1 2026 | $818.0M |
| Q4 2025 | $1.0B |
| Q3 2025 | $964.0M |
| Q2 2025 | $963.0M |
| Q1 2025 | $770.0M |
| Q4 2024 | $1.0B |
| Q3 2024 | $936.0M |
| Q2 2024 | $948.0M |
| Q1 2024 | $798.0M |
| Q4 2023 | $985.0M |
| Q3 2023 | $925.0M |
| Q2 2023 | $927.0M |
| Q1 2023 | $764.0M |
| Q4 2022 | $913.0M |
| Q3 2022 | $883.0M |
| Q2 2022 | $876.0M |
| Q1 2022 | $792.0M |
| Q4 2021 | $864.0M |
| Q3 2021 | $870.0M |
| Q2 2021 | $814.0M |
| Q1 2021 | $758.0M |
| Q4 2020 | $867.0M |
| Q3 2020 | $826.0M |
| Q2 2020 | $750.0M |
| Q1 2020 | $714.0M |
| Q4 2019 | $792.0M |
| Q3 2019 | $767.0M |
| Q2 2019 | $778.0M |
| Q1 2019 | $640.0M |
| Q4 2018 | $731.0M |
| Q3 2018 | $675.0M |
| Q2 2018 | $711.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
ORENCIA
| Period | Revenue |
|---|---|
| Q2 2026 | $1.0B |
| Q1 2026 | $818.0M |
| Q4 2025 | $1.0B |
| Q3 2025 | $964.0M |
| Q2 2025 | $963.0M |
| Q1 2025 | $770.0M |
| Q4 2024 | $1.0B |
| Q3 2024 | $936.0M |
| Q2 2024 | $948.0M |
| Q1 2024 | $798.0M |
| Q4 2023 | $985.0M |
| Q3 2023 | $925.0M |
| Q2 2023 | $927.0M |
| Q1 2023 | $764.0M |
| Q4 2022 | $913.0M |
| Q3 2022 | $883.0M |
| Q2 2022 | $876.0M |
| Q1 2022 | $792.0M |
| Q4 2021 | $864.0M |
| Q3 2021 | $870.0M |
| Q2 2021 | $814.0M |
| Q1 2021 | $758.0M |
| Q4 2020 | $867.0M |
| Q3 2020 | $826.0M |
| Q2 2020 | $750.0M |
| Q1 2020 | $714.0M |
| Q4 2019 | $792.0M |
| Q3 2019 | $767.0M |
| Q2 2019 | $778.0M |
| Q1 2019 | $640.0M |
| Q4 2018 | $731.0M |
| Q3 2018 | $675.0M |
| Q2 2018 | $711.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (5)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ORENCIA | ABATACEPT | 250MG | INJECTABLE;IV (INFUSION) |
| ORENCIA | — | 125MG/ML | Injection |
| ORENCIA | — | 125MG/ML | Injection |
| ORENCIA | — | 87.5MG/0.7ML | Injection |
| ORENCIA | — | 50MG/0.4ML | Injection |
5 products